{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:28:45Z","timestamp":1793651325739,"version":"4.5.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.amjmed.2026.05.016","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:45:25Z","timestamp":1779291925000},"page":"1683-1691.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Age-related efficacy of aspirin in secondary prevention of coronary artery disease: START-ANTIPLATELET registry and meta-analysis of randomized trials"],"prefix":"10.1016","volume":"139","author":[{"given":"Emanuele","family":"Valeriani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Di Nisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plinio","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gresele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Pengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria Maria","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Antonucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Santilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Pannunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-7455","authenticated-orcid":false,"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Violi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2026.05.016_bib0001","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein","volume":"56","author":"Roth","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0002","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/eurheartj\/ehad868","article-title":"Thromboxane biosynthesis and future events in diabetes: the ASCEND trial","volume":"45","author":"Petrucci","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0003","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American heart association\/American college of cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0004","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0005","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehad870","article-title":"Correction to: 2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European society of cardiology (ESC)","volume":"45","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0006","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3324\/haematol.2022.281006","article-title":"Reduced platelet glycoprotein ibalpha shedding accelerates thrombopoiesis and COX-1 recovery: implications for aspirin dosing regimen","volume":"108","author":"Simeone","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0007","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0008","article-title":"Circulating MRP8\/14 drives faster platelet COX-1 recovery via MRP4 impairing the duration of aspirin response","author":"Liani","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0009","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.108.768283","article-title":"Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk","volume":"118","author":"Eikelboom","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0010","doi-asserted-by":"crossref","first-page":"39143","DOI":"10.18632\/oncotarget.9826","article-title":"Age-related increase of thromboxane B2 and risk of cardiovascular disease in atrial fibrillation","volume":"7","author":"Pastori","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0011","doi-asserted-by":"crossref","unstructured":"Valeriani E., Sesso H., Pastori D., Menichelli A., Pignatelli P., Violi F. Age related clinical efficacy of aspirin for primary cardiovascular prevention: a systematic-review and meta-analysis. Manuscript accepted for publication at Thromb Haemost on 17 January 2025. 2025.","DOI":"10.1055\/a-2580-6931"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0012","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0013","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/bmj.1.5905.436","article-title":"A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction","volume":"1","author":"Elwood","year":"1974","journal-title":"Br Med J"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0014","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(79)92808-3","article-title":"Aspirin and secondary mortality after myocardial infarction","volume":"314","author":"Elwood","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0015","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0016","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0017","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Schupke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0018","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ahj.2015.12.014","article-title":"Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: a randomized, open-label trial","volume":"173","author":"Ueda","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0019","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0021","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0022","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1093\/eurheartj\/ehz185","article-title":"Randomized trial of ticagrelor versus. aspirin in patients after coronary artery bypass grafting: the TiCAB trial","volume":"40","author":"Schunkert","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0023","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease","volume":"384","author":"Jones","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0024","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.4244\/EIJ-D-21-00870","article-title":"Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial","volume":"18","author":"Ono","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0025","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","article-title":"Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis","volume":"406","author":"Valgimigli","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.000703","article-title":"High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (aspirin nonresponsiveness and clopidogrel endpoint trial)","volume":"1","author":"Pettersen","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0027","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/j.1538-7836.2004.01017.x","article-title":"A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial","volume":"2","author":"Woodward","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0028","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0029","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.122.062770","article-title":"Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study","volume":"147","author":"Kang","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jacc.2023.10.013","article-title":"Clopidogrel versus Aspirin monotherapy beyond 1 year after percutaneous coronary intervention","volume":"83","author":"Watanabe","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0031","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1093\/eurheartj\/ehae617","article-title":"Aspirin versus. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial","volume":"45","author":"Watanabe","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0032","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(25)00449-0","article-title":"Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial","volume":"405","author":"Choi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0033","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a veterans administration cooperative study","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0034","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/hc0502.103329","article-title":"Department of veterans affairs cooperative studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study","volume":"105","author":"Fiore","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0035","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S0002-9149(99)00091-0","article-title":"Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese antiplatelets myocardial infarction study (JAMIS) investigators","volume":"83","author":"Yasue","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0036","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1161\/01.CIR.103.25.3069","article-title":"Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery","volume":"103","author":"Huynh","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0037","first-page":"325","article-title":"Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon","volume":"9","author":"Breddin","year":"1980","journal-title":"Haemostasis"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0038","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jacc.2016.10.043","article-title":"Dual antiplatelet therapy versus Aspirin monotherapy in diabetics with multivessel disease undergoing CABG: FREEDOM insights","volume":"69","author":"van Diepen","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0039","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0149-2918(97)80058-6","article-title":"A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation","volume":"19","author":"Kunishima","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0040","doi-asserted-by":"crossref","first-page":"835","DOI":"10.7326\/0003-4819-114-10-835","article-title":"Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial","volume":"114","author":"Ridker","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0041","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/01.CIR.62.3.449","article-title":"The persantine-aspirin reinfarction study research group","volume":"62","year":"1980","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0042","first-page":"V63","article-title":"The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian study group","volume":"62","author":"Breddin","year":"1980","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0043","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.1980.03300330019023","article-title":"Controlled trial of aspirin in persons recovered from myocardial infarction","volume":"243","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0044","first-page":"235","article-title":"Early and late effects of coumarin therapy started before percutaneous coronary intervention: clinical, angiographic and cost-effective outcome of the balloon angioplasty and anticoagulation study (BAAS)","volume":"10","author":"Ten Berg","year":"2002","journal-title":"Neth Heart J"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0045","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)01180-X","article-title":"Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin reinfarction study (CARS) investigators","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0046","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0047","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0048","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ehj.2003.10.026","article-title":"Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study","volume":"25","author":"Herlitz","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0049","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-Month dual-antiplatelet therapy followed by Aspirin monotherapy after polymer-free drug-coated stent implantation: one-Month DAPT trial","volume":"14","author":"Hong","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0050","first-page":"365","article-title":"Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial","volume":"37","author":"Helft","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0051","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0052","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0053","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0054","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0055","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0056","first-page":"608","article-title":"Randomized comparison of novel biodegradable polymer and durable polymer-coated cobalt-chromium sirolimus-eluting stents: three-year outcomes of the I-LOVE-IT 2 trial","volume":"91","author":"Song","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0057","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0058","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-Month versus 12-Month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial","volume":"9","author":"Hong","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0059","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4244\/EIJ-D-17-00792","article-title":"Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C randomised clinical trial and OCT substudy","volume":"13","author":"Lee","year":"2018","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0060","first-page":"2510","article-title":"Three versus twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0061","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0062","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.amjcard.2019.11.033","article-title":"Comparison of age (<75 Years Versus >\/=75 Years) and platelet reactivity to the risk of thrombotic and bleeding events after successful percutaneous coronary intervention with drug-eluting stents (from the ADAPT-DES Study)","volume":"125","author":"Faggioni","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0063","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrd985","article-title":"Scientific and therapeutic advances in antiplatelet therapy","volume":"2","author":"Bhatt","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0064","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.amjmed.2005.03.041","article-title":"Low-dose aspirin increases aspirin resistance in patients with coronary artery disease","volume":"118","author":"Lee","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0065","first-page":"21","article-title":"Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease","volume":"10","author":"Liu","year":"2013","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0066","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.jacc.2007.11.080","article-title":"The role of aspirin in cardiovascular prevention: implications of aspirin resistance","volume":"51","author":"Gasparyan","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0067","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/jamacardio.2024.4335","article-title":"Aspirin for secondary prevention of atherosclerosis-evidence or dogma?","volume":"10","author":"Cleland","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0068","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1160\/TH15-03-0202","article-title":"Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk\/benefit profile to personalised treatment","volume":"114","author":"Santilli","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0069","article-title":"Factors associated with aspirin resistance in diabetic patients: a metabolic and inflammatory profile analysis","volume":"20","author":"Chen","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s40246-024-00699-1","article-title":"The associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis","volume":"18","author":"Li","year":"2024","journal-title":"Hum Genom"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0071","doi-asserted-by":"crossref","DOI":"10.3390\/medicina57010059","article-title":"Multifactorial background for a low biological response to antiplatelet agents used in stroke prevention","volume":"57","author":"Wisniewski","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0072","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1538-7836.2008.03122.x","article-title":"Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance","volume":"6","author":"Pignatelli","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0073","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/ars.2023.0373","article-title":"Aging and antithrombotic treatment","volume":"41","author":"Valeriani","year":"2024","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.amjmed.2026.05.016_bib0074","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1093\/eurheartj\/ehaf514","article-title":"Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial","volume":"46","author":"Wolfe","year":"2025","journal-title":"Eur Heart J"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326004328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326004328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:55:34Z","timestamp":1793649334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326004328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0002934326004328"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.05.016","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Age-related efficacy of aspirin in secondary prevention of coronary artery disease: START-ANTIPLATELET registry and meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}